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ABSTRACT 17 
 18 
Background 19 
Metabolic profiling is becoming increasingly popular to identify subtle metabolic 20 
variations induced by diet alterations and to characterize the metabolic impact 21 
of variations of the gut microbiota. In this context, fecal samples, that contain 22 
unabsorbed metabolites, offer a direct access to the outcome of diet - gut 23 
microbiota metabolic interactions. Hence, they are a useful addition to measure 24 
the ensemble of endogenous and microbial metabolites, also referred to as the 25 
hyperbolome. 26 
Scope and Approach 27 
Many reviews have focused on the metabolomics analysis of urine, plasma and 28 
tissue biopsies; yet the analysis of fecal samples presents some challenges that 29 
have received little attention. We propose here a short review of current 30 
practices and some practical considerations when analyzing fecal material using 31 
metabolic profiling of small polar molecules and lipidomics. 32 
Key Findings and Conclusions 33 
To allow for a complete coverage of the fecal metabolome, it is recommended to 34 
use a combination of analytical techniques that will measure both hydrophilic 35 
and hydrophobic metabolites. A clear set of guidelines to collect, prepare and 36 
analyse fecal material is urgently needed. 37 
  38 
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Highlights 39 
1. Untargeted metabolic profiling of fecal material is robustly achieved using 40 
NMR-based metabolomics 41 
2. Mass spectrometry is mostly used for targeted metabolic profiling of a 42 
class of molecules for deep coverage and high sensitivity 43 
3. Lipidomics profiles are extremely complex as they contain a mixture of 44 
endogenous, diet-related and microbial lipids that may be of interest for 45 
bacterial identification 46 
  47 
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INTRODUCTION  48 
The gut microbiota is a highly metabolically active community of micro-49 
organisms inhabiting all niches along the intestine, that is now recognized as a 50 
critical regulator of its host homeostasis.(O'Hara & Shanahan, 2006) It has been 51 
estimated that the gut microbiota as a whole contains 100 times more genes 52 
than human cells, hence its potential to be a key metabolic player. It is therefore 53 
expected that modifying the gut microbial balance would induce a shift in the gut 54 
metabolic environment that can in turn affect our own metabolism.  55 
The gut microbiota composition varies considerably over a lifetime.(Yatsunenko 56 
et al., 2012) It takes approximately two years to a newborn to acquire a stable 57 
GM population(Palmer, Bik, DiGiulio, & Relman, 2007) that will evolve through 58 
life under the pressure of various factors such as, for instance, diet, lifestyle and 59 
exposure to antibiotics, all commonly referred to as the ‘exposome’. (Claesson et 60 
al., 2011; Claus & Swann, 2013; Lozupone, Stombaugh, Gordon, & Jansson, 2012) 61 
Later in life, a loss of microbial diversity is generally observed with senescence. 62 
(Biagi, Candela, Fairweather-Tait, Franceschi, & Brigidi, 2011; Claesson et al., 63 
2011) As recently demonstrated, even perturbations of the circadian cycle have 64 
been observed to affect the balance of the gut microbial community. (Mukherji, 65 
Kobiita, Ye, & Chambon, 2013; Voigt et al., 2014) 66 
Diet is the main factor influencing gut microbiota composition since it provides 67 
microorganisms with their main organic carbon source.(Flint, Duncan, Scott, & 68 
Louis, 2015) This connection was recently further evidenced by a study 69 
demonstrating that a drastic change of diet such as switching from vegetarian to 70 
carnivorous and inversely can profoundly reorient the GM ecosystem in a very 71 
short period of time.(David et al., 2015) Thus, along genetic and other 72 
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 5
environmental factors, diet strongly contributes to the unique character of every 73 
individual’s gut microbiota.  74 
Bacteria have a high metabolic activity that generates a wide range of products 75 
such as organic acids, alcohols and gas that may become available for the host or 76 
other commensal bacteria for cross-feeding. This symbiotic activity shapes the 77 
gut metabolic environment. Complex carbohydrates, that cannot be digested in 78 
the upper gastrointestinal track and are a major source of carbon for colonic 79 
bacteria.(Scott, Duncan, & Flint, 2008) Their fermentation results in the 80 
production of short chain fatty acids (SCFAs: acetate, propionate, butyrate and 81 
valerate) that play an important role in human health.(Besten, van Eunen, Groen, 82 
& Venema, 2013) Other food components such as lipids and proteins can largely 83 
impact the composition of the gut microbiota and its metabolic 84 
activity.(Sonnenburg & Sonnenburg, 2014) Endogenous secretions such as the 85 
bile acids contained in bile are important regulators of the gut microbiota. 86 
Reciprocally, gut bacteria are known to extensively alter the structure of sterols 87 
that leads to the formation of secondary and tertiary bile acids.(Sayin et al., 88 
2013) This is an example of a major gut microbiota-host interplay that 89 
contributes to regulating the absorption of dietary lipids during digestion. Hence, 90 
the diet-gut microbiota interaction plays a key role in the metabolic homeostasis 91 
of its host. It is therefore of utmost importance to understand the biological 92 
mechanisms that underlie this complex relationship. Systems biology 93 
approaches that study a system as a whole (e.g. a micro-organism within a host, 94 
the interactions occurring within a community of bacteria etc.) are increasingly 95 
popular to decipher these interactions. In particular, metabolic profiling 96 
techniques are tremendously useful to understand the metabolic pathways 97 
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regulated through the host-gut microbiota interaction. A variety of sample types 98 
ranging from biofluids to tissue biopsies can be analyzed to capture the systemic 99 
metabolic response to the exposome. Of particular interest, feces are easily 100 
accessible and provide a non-invasive window to study the outcome of the diet-101 
gut microbiota-host interaction through the analysis of remaining unabsorbed 102 
metabolites. Yet, the analysis of fecal samples for metabolic profiling has 103 
received little attention. In this review, we will explore the dominant 104 
technologies that are commonly applied to assess the fecal metabolome and 105 
discuss about practical aspects that must be considered when dealing with this 106 
material. 107 
 108 
NMR-based metabolomics of fecal samples 109 
Metabolic profiling, also referred to as metabolomics, is mostly achieved using 110 
two analytical platforms: nuclear magnetic resonance (NMR) spectroscopy and 111 
mass spectrometry (MS) to evaluate the metabolic composition of a chosen 112 
biological matrix. These techniques allow the simultaneous measurement of a 113 
wide range of metabolites in a sample, and when combined, offer a large 114 
coverage of the metabolome (i.e. the set of metabolites in a sample). 115 
Untargeted metabolic profiling by 1H NMR spectroscopy measures all 116 
metabolites with nonexchangeable protons that are present in a sample in a 117 
relatively high concentration (in the micromolar range). Because it is highly 118 
reproducible, is cost effective and usually requires only a few simple preparation 119 
steps, NMR-based metabolic profiling has been widely applied to the analysis of 120 
virtually all biological matrices, including feces. (Li et al., 2011; Martin et al., 121 
2010; Saric et al., 2008)  122 
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 7
In humans, 1H NMR-based metabolic profiling of fecal material has been 123 
successfully applied to assess the impact of the composition of the gut 124 
microbiota on the gut metabolic environment in the context of ulcerative colitis 125 
(UC) and irritable bowel syndrome (IBS).(Le Gall et al., 2011) A similar approach 126 
was applied to monitor the gut microbial metabolic activity in elderly (Claesson 127 
et al., 2012). In this study, it was possible to cluster patients according to their 128 
community setting (length of hospital care) based on fecal water profiling. A 129 
recent study also demonstrated the possibility of evaluating independent 130 
bacterial contributions at a species level to the gut metabolic environment using 131 
this technique. (Le Roy et al., 2015). Applied to the monitoring of probiotic 132 
consumption, it was possible to detect faecal metabolic modifications in 133 
response to increased Bifidobacterium in the colon (Ndagijimana et al., 2009)  134 
In animal models, profound reorientation of the gut microbial community 135 
induced by antibiotics in mice was associated to modifications of fecal metabolic 136 
profiles measured by the same technique. This was mainly associated to a 137 
modification in the fecal content in amino acids and SCFAs.(Yap et al., 2008). 138 
Similarly, Romick-Rosendale et al., (Romick-Rosendale et al., 2009) also showed 139 
a modification of murine fecal metabolic profiles in response to antibiotic 140 
treatments. NMR-based metabonomics analysis of fecal water also proved to be 141 
able to differentiate age groups in mice. (Calvani et al., 2014) Finally NMR-based 142 
metabonomics can be applied to nutrition (also referred to as 143 
nutrimetabonomics) (Claus & Swann, 2013) to access modification of the gut 144 
metabolic environment in response to diet modulation. As an example, a study 145 
by De Filippis et al., (De Filippis et al., 2015) used NMR-based metabonomics to 146 
evaluate the impact of a Mediterranean diet on gut microbiota metabolic activity. 147 
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 8
The study demonstrated that following a Mediterranean diet improved the 148 
detection of SCFAs in fecal waters compared with a western diet. Similarly, fecal 149 
metabolic modifications have been observed in response to food 150 
supplementation investigated in in vitro gut models. (Frost et al., 2014).  151 
Since fecal samples contain a complex mixture of metabolites, most NMR-based 152 
metabolic profiling studies use a selective NOESY experiment with water 153 
presaturation applied during recycle delay and mixing time to detect signals 154 
caused by small molecular weight molecules as well as some lipids. This is often 155 
referred to as the NOESYPR1D experiment [RD-90º-t1-90º-tM-90º-ACQ], where 156 
RD is the recycle delay, t1 a short interval of about 3 μs, tM the mixing time of 157 
approximately 100 ms and ACQ the FID acquisition period. Interestingly, a 158 
number of studies investigating fecal samples have also used a CPMG (Carr-159 
Purcell-Meiboom-Gill) experiment, (Bjerrum et al., 2014; Li et al., 2011) which 160 
uses t2 filtering to reduce signal resonance from large macromolecules. 161 
(Meiboom & Gill, 1958) However, this should be considered with care since the 162 
number of loops and length of echo time that must be optimized for each CPMG 163 
experiment would determine the signal/noise ratio, therefore preventing 164 
absolute quantification. This is not an issue when only relative quantifications 165 
are needed.  166 
Preparation of fecal material for metabolomics studies 167 
 168 
Recently, Deda et al. reviewed sample preparation methods for fecal samples for 169 
metabolomic analysis.(Deda, Gika, Wilson, & Theodoridis, 2015) They provided a 170 
comprehensive overview of fecal sample preparation for NMR, GC-MS and LC-MS 171 
analysis including some critical aspects and specific requirement of the different 172 
technologies. Therefore, we will not cover sample preparation in details here but 173 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 9
a summary of the protocols and methods used in previously published research 174 
papers are presented in Table 1. However, it is noteworthy that this review 175 
highlighted the lack of consensus about sample preparation for both metabolic 176 
profiling technologies. For sample extraction, it seems that a dilution of 1 volume 177 
of feces material for 2 volumes of PBS buffer is most commonly used. The buffer 178 
is generally composed of a mixture of H2O and D2O (minimum 10 %) in various 179 
amounts, with an adjusted pH of 7.4 and an internal standard to serve as NMR 180 
reference. The most common internal reference is 3-(trimethylsilyl)-2,2,3,3-181 
propionate-d4 (TSP). Deda et al. discuss that TSP signal intensity can be affected 182 
by pH but so far, the only alternative is 2,2-dimethyl-2-silapentane-5-sulfo- nate-183 
d6 (DSS). However, unlike TSP, DSS has multiple small resonances in addition to 184 
the main resonance at 0 ppm that may interfere with other signals and therefore 185 
it should be used at a very low concentration (0.01% would be recommended). 186 
Homogenization of fecal material can be done directly in the NMR buffer that will 187 
be used for NMR analysis, minimizing the number of sample processing steps 188 
that may alter metabolic profiling. However, it also appears that a 189 
water/methanol extraction tends to improve the overall recovery of fecal 190 
metabolites. Nevertheless it was also argued in a publication by Jacobs et al., 191 
(Jacobs et al., 2007) that methanol extracts were less representative of the real 192 
metabolic composition of the fecal water encounter in the colon and therefore of 193 
the metabolite pool that interacts with the intestinal membrane.  194 
 195 
Mass spectrometry-based metabolomics of fecal samples 196 
Untargeted metabolic profiling using MS-based techniques is more sensitive than 197 
NMR (in the nanomolar range) but often generates a large amount of unknown 198 
signals and as a consequence, these techniques have been mostly used for 199 
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targeted metabolomics, where the method is optimized to the detection of a 200 
specific class of samples. MS-based metabolic profiling is usually achieved using 201 
either gas chromatography (GC-MS) or liquid chromatography (LC-MS). 202 
 203 
GC-MS based metabolomics 204 
The group of Sébédio presented two GC-MS methods to analyze the metabolome 205 
of fecal water. In their first study they used an ethyl chloroformate derivatization 206 
(Gao et al., 2009). In fecal water samples of healthy subjects 73 compounds were 207 
identified and thereof 34 validated by reference standards. The second study 208 
applied trimethylsilylation and identified 133 compounds (including amino 209 
acids, carbohydrates short and long chain fatty acids and phenolics) in human 210 
fecal water and the majority validated by authentic standards (Gao, Pujos-211 
Guillot, & Sébédio, 2010). In both studies several extraction conditions were 212 
tested and the highest recovery of metabolites detected for neutral and basic pH 213 
which was confirmed also by others (Deda et al., 2015). However, it has been 214 
suggested that increasing pH from 6 to 7 may decrease the loss of volatile SCFA 215 
during lyophilization (Gao, Pujos-Guillot, & Sébédio, 2010). 216 
Phua et al. presented a GC-TOF-MS analysis of feces after freeze drying followed 217 
by oximation and silylation (Phua, Koh, Cheah, Ho, & Chan, 2013). The authors 218 
argue that removal of a variable content of water increased the reproducibility of 219 
sample preparation. They identified 107 metabolites by matching with different 220 
mass spectra libraries. However, only a few analytes were confirmed by 221 
reference substances. This method was applied in detection of colorectal cancer 222 
(Phua et al., 2014). Main markers for CRC differentiation include decreased level 223 
of fructose, nicotinic acid and linoleic acid in CRC patients. 224 
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 11
Using a similar methodology, Weir et al. analyzed the fecal metabolome in CRC 225 
patients (Weir et al., 2013). Metabolite identification was based on database 226 
matching. In agreement with Phua et al. they detected decreased linoleic acid in 227 
CRC patients compared to healthy controls. Moreover, reduced level of oleic and 228 
elaidic acids were found in CRC patients. In contrast to these fatty acids (FAs) 229 
myristic acid and several amino acids were increased in CRC patients. It is 230 
noteworthy that fatty acid identification does not differentiate double bond 231 
positions. 232 
A very efficient approach to analyze volatile organic compounds (VOC) of feces is 233 
headspace solid-phase microextraction (SPME). Volatile metabolites are 234 
adsorbed to polymer coated fibers which are analyzed by GC-MS. Typically the 235 
analyte spectrum includes hydrocarbons, alcohols, aldehydes and organic acids 236 
(primarily short chain) and their esters. Dixon et al. tested different fibers to get 237 
a comprehensive coverage of VOCs (Dixon et al., 2011). Ahmed et al investigated 238 
fecal VOCs in patients with irritable bowel syndrome, active Crohn’s disease, 239 
ulcerative colitis and healthy controls (Ahmed, Greenwood, de Lacy Costello, 240 
Ratcliffe, & Probert, 2013). They identified 240 metabolites which allowed a 241 
differentiation of patients with irritable bowel syndrome from patients with 242 
inflammatory bowel diseases and healthy controls. 243 
 244 
LC-MS based metabolomics 245 
In contrast to GC-based methods, LC-MS usually does not require metabolite 246 
derivatization but is restricted to analytes containing polar groups. Cao et al. 247 
used UPLC-MS/TOF-MS to analyze the fecal metabolome in patients with liver 248 
cirrhosis and hepatocellular carcinoma (HCC) (Cao et al., 2011). Fecal samples 249 
were homogenized, centrifuged and injected after filtration. Metabolic features 250 
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were analyzed by multivariate data analysis. Chenodeoxycholic acid, 7-251 
ketolithocholic acid, urobilinogen, urobilin, lysophosphatidylcholine (LPC) 16:0 252 
and 18:0 were found to discriminate between healthy controls and patients with 253 
liver cirrhosis and HCC. Whereas LPC species were found in increased levels, the 254 
other discriminatory markers were decreased in the patient samples. The 255 
identities of these markers were confirmed by comparison of chromatographic 256 
retention and product ion spectra with authentic standards. 257 
A study by Jimenez-Girón investigated changes in the fecal metabolome related 258 
to the consumption of red wine (Jiménez-Girón et al., 2015). Feces samples were 259 
analyzed after mixing with saline solution, centrifugation and filtration by 260 
UHPLC-TOF-MS. Mass features were subjected to statistical analysis and 37 261 
metabolites were found to be related to wine intake. Metabolite identification 262 
was performed by database searching and confirmation by authentic standards. 263 
This way 14 metabolites could be identified tentatively, 6 mass features match to 264 
standards (m/z and retention time).  265 
The fecal metabolome of rats with chronic renal failure were analyzed by Zhao et 266 
al. (Zhao, Cheng, Wei, Bai, & Lin, 2012). Homogenized fecal samples were 267 
extracted with acetonitrile and analyzed by UPLC-Q-TOF-MS. Both polarities 268 
including fragment ions were recorded and used for identification and validation 269 
of mass features. Except an increase of adenine (used to induce kidney failure), 8 270 
lipid metabolites were found decreased in rats with chronic renal failure. 271 
An interesting approach to profile amine- and phenol-containing metabolites 272 
was presented recently by Su and colleagues (Su et al., 2015). Dried fecal 273 
samples are extracted sequentially with water and acetonitrile followed by 274 
derivatization with dansyl chloride. As an internal standard an aliquot of a 275 
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pooled fecal extract was added which was derivatized with 13C-labelled dansyl 276 
chloride. Dansylation improves both LC separation efficiency and MS response of 277 
the compounds. 6200 peaks were detected in 237 different samples and 67 278 
metabolites (mainly amino acids) were identified based on mass and retention 279 
time matching to a dansyl standard library.  280 
In summary, both GC- and LC-based metabolomics studies are able to discover a 281 
number of differentially regulated metabolic features in fecal samples in various 282 
studies. However frequently, only a few of these features could be identified. 283 
Moreover, several studies did not prove the identity by authentic standards but 284 
only by matching of m/z values to database entries. In general, GC-MS based 285 
studies identify an increased number of metabolites which may partly reflect the 286 
superior chromatographic resolution and peak shape of GC compared to LC 287 
methods. This allows a more reliable extraction and comparison of metabolic 288 
features between different samples. Additionally, GC usually provides mass 289 
spectra generated by ionization-induced fragmentation that are useful for 290 
metabolite identification. A disadvantage of GC analyses is a more laborious 291 
sample preparation including the need of derivatization as a potential source of 292 
artifacts. Conversely, GC-MS clearly shows advantages compared to LC-MS in 293 
terms of deleterious matrix effects. So it is generally accepted that quantification 294 
of analytes by LC-MS requires internal standards, ideally stable isotope labeled 295 
for each analyte. Therefore a major source of errors of LC-MS metabolic profiling 296 
may be related to undiscovered matrix effects especially in heterogeneous 297 
sample material like feces. Consequently, in order to provide solid data 298 
metabolomics studies should validate their biomarkers by quantitative analysis 299 
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using authentic standards and internal standards especially when LC-MS is 300 
applied at least in a representative cohort.  301 
 302 
Mass spectrometry-based targeted metabolic analysis 303 
In contrast to untargeted analysis, targeted analysis is confined to a limited set of 304 
analytes. These methods are optimized for high analyte recoveries during 305 
sample preparation and a reproducible, accurate quantification of the target 306 
molecules. Most methods rely on internal standards (mandatory for LC-MS), 307 
calibration lines and method validation shows their performance. 308 
 309 
SCFA 310 
An excellent example for targeted analysis of potential biomarkers is the 311 
quantitation of short chain fatty acids (SCFA). A recent study by Han et al. 312 
presented a LC-MS/MS method for SCFA quantification in human feces (Han, Lin, 313 
Sequeira, & Borchers, 2014). SFCAs are converted to 3-nitrophenylhydrozones 314 
(3NHPH) which are separated by reversed phase chromatography and detected 315 
in negative ion mode. The method covers 10 straight- and branched chain SCFAs. 316 
In an elegant way, this study introduced an internal standard for every analyte 317 
by conversion of a standard mixture with a 13C6-labeled derivatization reagent. 318 
This method showed a high reproducibility and analysis of human fecal samples 319 
revealed an increased fraction of branched-chain SCFA in T2D patient compared 320 
the other analyzed samples.  321 
In contrast to LC-MS/MS analysis, GC-MS may rely on a fewer number of internal 322 
standards since matrix effects are less pronounced. A study by Zheng et al. 323 
quantified SCFAs and branched-chain amino acids (BCAAs) in feces and other 324 
biological materials using D3-caproic acid as internal standard (Zheng et al., 325 
2013) after propyl chloroformate derivatization.  326 
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 327 
Analysis of sterols and bile acids in faeces 328 
Sterols and bile acids belong to another class of analytes studied for a long time 329 
in feces by targeted analysis. Cholesterol is an essential component of all 330 
mammalian cell membranes and it is the precursor of steroid hormones and bile 331 
acids. There has been a long interest in the intestinal metabolism of cholesterol 332 
because the gut microbiome is highly involved in the balance between 333 
absorption, excretion and metabolism. Between 34-57% of dietary cholesterol is 334 
absorbed from the human intestine (Grundy et al., 1977). Fecal excretion of total 335 
neutral sterols has been reported to range between 350-900 mg/day, of which 336 
20% is cholesterol. There are several primary sources of fecal cholesterol: 337 
unabsorbed from the diet, bile and intestinal epithelium. It is well-known that 338 
the luminal cholesterol can be metabolized by the gut microbiota. This 339 
cholesterol escaping intestinal absorption is degraded to coprostanol through 340 
reduction of the double bond at C-5. (Figure 1) Coprostanone is also produced in 341 
a lesser extent. (Eyssen et al., 1974; Lichtenstein, 1990; Gerard, 2013). In human 342 
feces, cholesterol derivatives have been reported in the following proportions: 343 
coprostanol 65%, cholesterol 20%, coprostanone 10 %. (Figure 1) Other minor 344 
derivatives include cholestanone, cholestanol and epicoprostanol.  345 
Many attempts have been made to isolate bacteria capable of reducing 346 
cholesterol to coprostanol from human and animal faeces (Snog-Kjaer et al., 347 
1956; Crowther et al., 1973). Certain anaerobic bacteria from human faeces are 348 
known to hydrogenate cholesterol in vitro. Cholesterol reduction by common 349 
intestinal bacteria such as Bifidobacterium, Clostridium, and Bacteriodes has 350 
also been reported and reviewed extensively (Gerard, 2013). In addition, 351 
reference values have been generated for fecal excretion of cholesterol and 352 
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coprostanol (Benno et al., 2005) to differentiate between high-, low- and non-353 
converters. 354 
Bile acids are derived from cholesterol and are produced by every class of 355 
vertebrate animals and show substantial diversity across species (Hofmann et 356 
al., 2010). In bile, bile acids rapidly form mixed micelles with secreted 357 
cholesterol and phospholipids. Bile acids enter the intestine as di- and 358 
trihydroxylated acyl conjugates, in mammals with the amino acids taurine and 359 
glycine (Hofmann, 2009). In the intestinal lumen, conjugated bile acids directly 360 
affect the microbiota because they exert antimicrobial properties besides 361 
stimulating enterocytes to secrete undefined antimicrobial compounds 362 
(Hofmann et al., 2006). Conversely, gut bacteria structurally alter bile acids 363 
through deconjugation of taurine, glycine and sulfate moieties and hydroxylation 364 
of the sterol backbone.  365 
During digestion, bile acids facilitate lipid absorption by stabilizing lipid micelles. 366 
Since bile acids have various degrees of hydrophobicity, and therefore various 367 
stabilizing properties, the bile acid composition of the bile is an important factor 368 
that regulates fat absorption. The enterohepatic cycle of bile acids is a key 369 
regulator of hepatic bile acid de novo synthesis and cholesterol excretion. Indeed, 370 
bile acids undergo extensive reabsorption by active and passive routes so that 371 
95 % of secreted bile acids are reabsorbed daily. Since deconjugated bile acids 372 
are less polar, passive diffusion is reduced and it has been shown that active 373 
deconjugation by gut bacteria increases the overall excretion of bile acids in 374 
feces, hence the role of bacteria in regulating fecal cholesterol loss (Claus et al., 375 
2011; 2008; Kellogg, Knight, & Wostmann, 1970; Sayin et al., 2013). In human, a 376 
limited number of commensal bacteria are capable of removing the 7-hydroxyl 377 
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group from di- and trihydroxy bile acids and 7-deoxy species are formed. The 378 
most common 7-deoxy bile acids are lithocholic and deoxycholic acid. Many 379 
excellent reviews exist in the recent literature covering bile acid function, 380 
signaling and therapeutic potential (Ridlon et al., 2006; Hofmann et al., 2008; 381 
2009; Trauner et al., 2010; Hagey et al., 2013). 382 
 383 
Sample Preparation and Instrumental Strategies for Targeted Metabolomics 384 
Analysis 385 
SCFAs are volatile and therefore freeze drying of stool samples may result in 386 
lower recovery. Han et al. used homogenized samples and extracted SCFAs by 387 
addition of 50% aqueous acetonitrile (Han, Lin, Sequeira, & Borchers, 2014). 388 
These extracts were subjected directly to derivatization with 3-389 
nitrophenylhydrazine HCl. Zheng et al. used 0.005 M aqueous NaOH to 390 
homogenize fecal samples at 4°C to protect the volatile SCFAs (Zheng et al., 391 
2013). The homogenates were derivatized with propyl chloroformate and 392 
extracted with hexane extraction for GC-MS analysis. 393 
Extensive overviews of state-of–the-art methods to analyze fecal steroids can be 394 
found in the literature, e.g. (Story & Furumoto, 1991; Perwaiz et al., 2002; 395 
Griffiths & Sjövall, 2010) . The first and often referred methods for fecal steroid 396 
and bile acid analysis were a combination of thin-layer chromatography and gas-397 
liquid chromatography published 1965 by Grundy, Miettinen and co-workers 398 
(Grundy et al., 1965; Miettinen et al., 1965). Sample pretreatment included 399 
homogenization, saponification and liquid/liquid extraction followed by thin-400 
layer chromatography and trimethylsilylation. Individual components are then 401 
quantitatively measured by gas-liquid chromatography equipped with a flame 402 
ionization detector. Bile acids underwent a methylation step before thin-layer 403 
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chromatography. This approach was applied in many studies for the analysis of 404 
endogeneous and exogeneous (labelled) compounds.(Spritz et al., 1965; Grundy 405 
et al., 1969). Evrard and Janssen suggested a method for bile acid analysis which 406 
took advantage of a different extraction scheme and an alternate derivatization 407 
(Evrard & Janssen, 1968). The method is based on heating in presence of acetic 408 
acid and extraction with toluene. Quantification was done as methylketone 409 
derivatives. In the 1980s methods with subfraction steps have been proposed to 410 
isolate taurine and glycine conjugated and sulphated bile acids (Setchell et al., 411 
1983; Owen et al., 1984) using GC analysis. Nowadays, the most common 412 
strategies to analyze sterol profiles including cholesterol, coprostanol and 413 
coprostanone in faeces are based on GC-MS. The sample preparation protocol 414 
includes repeated sampling for better representativeness, a dilution step, 415 
hydrolyzation of esterified sterols, extraction with a mixture of hexane and 416 
ethanol and derivatization (Lutjohann et al., 1993; Midtvedt et al., 1990; Andrasi 417 
et al., 2011). For example, Korpela et al. suggested a very detailed protocol which 418 
included a 72 h sampling of faeces, methanol-chloroform extraction, separation 419 
of free and esterified sterols with a Lipidex-5000 column, saponification, 420 
separation of hydroxylated and oxo-forms by a second column, and trimethylsilyl 421 
derivatization followed by GCMS (Korpela, 1982). LC-MS and MS/MS have also 422 
been widely exploited for bile acid analysis of human urine, plasma/serum, bile 423 
and also feces (Perwaiz et al., 2002; Hagio et al., 2009; Griffiths & Sjövall, 2010). 424 
Quantification is best performed by addition of isotope labeled internal 425 
standards. These should be added as early as possible in the analytical process so 426 
as to account for analyte loss during sample preparation.  427 
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Bile acids can usually be extracted from fluids and tissues with ethanol, methanol 428 
or acetonitrile. An ethanol fraction may be followed by extraction with a less 429 
polar solvent, such as chloroform, to recover less polar bile acid derivatives (e.g., 430 
the fatty acid esters) and bile acids remaining in the lipophilic residue (Griffiths 431 
et al., 2010). Batta et al. compared different methods to extract fecal bile acids 432 
and sterols (Batta et al., 1999) to suggest a simplified method of extraction. 433 
However, this is based on the assumption that fecal bile acids are unconjugated 434 
(Setchell et al., 1983), which is not a valid assumption for many clinical 435 
conditions, especially when subjects have been exposed to oral antibiotic 436 
treatments that have affected the gut microbial ecosystem.  437 
Lipidomics 438 
 439 
Parallel to metabolomics, lipidomics emerged during the past decade as a 440 
specialized discipline. Today virtually a full quantitative coverage of the lipidome 441 
is possible by mass spectrometric methods (Wenk, 2010).  442 
In contrast to global metabolomics, lipidomic analysis mostly relies on lipid 443 
extracts prepared by extraction with apolar solvents like chloroform (Bligh & 444 
Dyer, 1959) or MTBE (Matyash, et al., 2008). The complexity of these extracts is 445 
greatly reduced compared to protein precipitates frequently applied for 446 
untargeted metabolomics as polar analytes are removed. 447 
Up to now there are only a few studies of the fecal lipidome. Gregory et al. 448 
compared different extraction methods for lipidomics profiling by LC-HR-MS 449 
(high resolution MS) (Gregory et al., 2013). Stools of preterm infants were 450 
homogenized in water and lipophilic metabolites were extracted using either 451 
dichloromethane or a MTBE/hexafluoroisopropanol mixture. Additionally, the 452 
effect of pressure cycling on the extraction of lipid species was investigated. 453 
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Polar species like lyso-lipids showed a higher response after MTBE extraction 454 
whereas increased responses were observed after dichloromethane extraction 455 
for more hydrophobic species. The effect of pressure cycling does not show a 456 
consistent increase of the lipid species response for both extraction methods. 457 
Analysis by reversed phase chromatography couple to HR-MS was performed in 458 
both positive and negative ion modes. 304 lipid species were identified by 459 
unique monoisotopic m/z and retention time including 29 460 
phosphatidylethanolamine (PE), 22 phosphatidylcholine (PC), 14 461 
phosphatidylglycerol (PG), 88 triacylglycerol, 19 diacylglycerol and interestingly 462 
50 ceramide species.  463 
Recently, Davis and colleagues analyzed stools from mice fed a high fat or control 464 
diet with or without induction of colitis-associated tumors (Davies et al., 2014). 465 
Feces was homogenized by repeated freeze-thawing, minced to powder and 466 
extracted with a modified Bligh and Dyer method. Samples were quantified by 467 
shotgun lipidomics. However, mass spectra displayed very low intensities. The 468 
selection of dioleoyl species of PE, PS, PI as internal standards has to be 469 
considered as a potential source of error for quantification since these species 470 
may be present in feces (PE and PI 36:2 were detected by Gregory et al. (Gregory 471 
et al., 2013)). A general problem of this study and also a number of metabolomics 472 
studies is the annotation of lipid species. Davis et al. showed detailed 473 
annotations including even double bond positions of the fatty acyls. Such 474 
structural differences usually may not be resolved by standard lipidomic or 475 
metabolomics methods. Most methods determine the number of carbons and 476 
number of double bonds with the acyl chains. Therefore, it is recommended to 477 
annotate only structural details which are resolved by the analysis (Liebisch et 478 
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al., 2013). Moreover, common shorthand nomenclature provides a standard for 479 
reporting and searching of lipid species including deposition in and retrieval 480 
from databases.  481 
Figure 2 presents the result of a lipidomic analysis of a fecal sample using a 482 
method that has been applied to a variety of sample types such as plasma 483 
(Sigruener et al., 2014), lipoproteins (Scherer, Böttcher, & Liebisch, 2011), cells 484 
(Leidl, Liebisch, Richter, & Schmitz, 2008), cell culture (Binder, Liebisch, 485 
Langmann, & Schmitz, 2006) and tissues (Hebel et al., 2015). Fecal samples were 486 
homogenized including bead-based grinding and subjected to liquid extraction 487 
according to Bligh and Dyer (Bligh & Dyer, 1959). Analysis by flow injection ESI-488 
MS/MS using lipid class specific head group scans revealed huge differences 489 
between the individual samples. For example, we could find substantial 490 
concentrations of PG in some samples whereas other samples showed only 491 
minor PG content (Figure 2). Similar observations were made for other lipid 492 
classes. Additionally, the method of homogenization and extraction may greatly 493 
influence lipid species recovery. So sample preparation may determine whether 494 
analysis of lipids is confined to “easily accessible” lipids or includes also “hardly 495 
extractable” bacterial lipid. Bacterial lipids could be of particular interest since 496 
they are used as chemotaxonomic parameter to classify and identify bacterial 497 
(Busse, Denner, & Lubitz, 1996). However, bacterial lipids also increase the 498 
complexity of the fecal lipidome. So a number of additional fatty acids usually not 499 
or only present at low concentrations in mammalian cells are found in bacteria 500 
such as branched chain, cyclopropane and hydroxyl fatty acids. In summary, an 501 
accurate analysis of the fecal lipidome poses a great challenge especially due to 502 
its high complexity and high variability. 503 
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NMR has also been used for structural analyses and quantification of lipid 504 
species including lipoproteins (Bou Khalil et al., 2010; Sander et al., 2013; 505 
AlaKorpela et al., 1996; Fernando et al., 2010). 31P-NMR is an attractive method 506 
to investigate phospholipid molecules due to the fact that all phospholipids have 507 
at least one phosphorous nucleus and this NMR active isotope occurs at a natural 508 
abundance of 100% and has got a high gyromagnetic ratio. Therefore, high 509 
resolution 31P-NMR spectroscopy has successfully been employed to determine 510 
the phospholipid composition of tissues and body fluids. Comprehensive reviews 511 
with many applications can be found in the literature (Schiller & Arnold, 2002; 512 
Schiller et al., 2007). However, we could not identify any study that applied NMR 513 
spectroscopy for lipid investigations in fecal samples. 514 
 515 
Final considerations 516 
It is noteworthy that although extremely useful and widely used, as illustrated by 517 
this review, fecal materials reliably reflect the microbial activity of the distal 518 
colon, which is moderately representative of the rest of the gastro-intestinal 519 
tract. For example, although it is commonly accepted that SCFAs measured in 520 
feces are an indicator of colonic production by gut bacteria, it is important to 521 
remember that these metabolites are quickly absorbed by the intestinal 522 
membrane and an increased detection in feces may also reflect a poorer 523 
absorption. To overcome this issue, metabolic profiling techniques can be 524 
applied on luminal content collected in various sections of the gastro-intestinal 525 
track, although this implies a more invasive sample collection. Fecal water 526 
profiling by NMR spectroscopy has been widely referenced for numerous animal 527 
models such as rodents(Romick-Rosendale et al., 2009) and horses(Escalona et 528 
al., 2014) as well as humans,(Jacobs et al., 2008) providing a database for future 529 
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investigations. This is also extremely useful for similar evaluations performed on 530 
fecal waters derived from in vitro batch cultures that simulate digestion by the 531 
gut microbiota. Even if in vitro models are not a perfect representation of the 532 
host-gut microbiota interplay, they provide a valuable overview of the microbial 533 
activity in the gut in controlled conditions. For instance, metabolic profiling of 534 
samples derived from such in vitro gut models has been recently applied to 535 
compare the impact of diet on human and baboon gut microbial activity.(Frost, 536 
Walton, Swann, & Psichas, 2014) 537 
Another important consideration when analyzing feces metabolome, and 538 
particularly fecal bile acids, is the irregularity of bile secretion and the 539 
inhomogeneity of fecal samples as carefully studied by Setchell et al., who 540 
demonstrated that this was strongly correlated with diet patterns (Setchell et al., 541 
1987). This is particularly relevant to human studies since humans tend to have 542 
a defined regular feeding pattern with set time and number of meals per day 543 
(unlike rodents that tend to feed all night, and from time to time during the day). 544 
As a consequence, it is recommended to analyze aliquots of thoroughly 545 
homogenized 4–5 day collections of feces. 546 
Finally, since one of the main factors influencing the gut metabolic environment 547 
is the microbiome, it is important to assess the microbial composition of the fecal 548 
material when possible, using 16S rRNA sequencing or metagenomics when 549 
possible, although these methods are not fully quantitative. Such metabolic 550 
associations with gut bacteria should also be interpreted carefully as it is not 551 
always possible to differentiate the host from the bacterial metabolic activity. 552 
This is particularly true for amino acids that can be released by dead host cells or 553 
be derived from protein digestion by host and bacterial enzymes. Typical 554 
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bacterial metabolites include SCFAs, some organic acids such as formate and by-555 
products of protein degradation such as indole. However, many fecal metabolites 556 
derive from host-bacterial co-metabolism, which is typically the case for 557 
secondary and tertiary bile acids. 558 
 559 
To summarize, the measurement of the fecal metabolome is becoming 560 
increasingly popular as it provides an easy estimate of the diet-gut microbiota-561 
host metabolic interaction. However, there is a need for establishing clear 562 
guidelines for fecal sample collection, preparation and analysis for metabolic 563 
profiling. Both NMR and MS-based metabolic profiling are complementary 564 
techniques and none of them to date is able to holistically assess the fecal 565 
metabolome. Instead, it is recommended that a combination of methods is used 566 
to extend the metabolic coverage.  567 
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FIGURE CAPTIONS 1012 
Figure 1: Estimated proportion of fecal cholesterol derivatives in humans. 1013 
 1014 
Figure 2: Neutral loss (NL) of 189 of lipid extracts prepared from fecal samples. 1015 
Suspensions of human fecal samples in water/methanol (1/1) were subjected to 1016 
bead-based homogenization. Homogenates were extracted according to Bligh 1017 
and Dyer (Bligh & DYER, 1959). Crude lipid extracts were analyzed by direct 1018 
flow injection analysis as described previously (Matyash et al., 2008). Displayed 1019 
are NL 189 spectra, specific for phosphatidylglycerol (PG), of three different 1020 
samples normalized to the highest intensity.  1021 
 1022 
Table 1: Summary of published studies applying metabolomics to study fecal 1023 
samples using NMR and MS platforms. Summary of protocols and main outcomes 1024 
are included.  1025 
Key: GC-FID: Gas chromatography- Flame ionization detector; GC-MS: Gas 1026 
chromatography-Mass spectrometry; LC-MS: Liquid chromatography-Mass 1027 
spectrometry; UPLC-MS: Ultra-Performance Liquid Chromatography-Mass 1028 
spectrometry 1029 
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Analytical 
technique 
Study aim Sample 
preparation 
overview 
Material / buffer Measurement Main results References 
NMR 400 MHz Aging in mice  1:4 (wN/Av) feces 
in deuterated PBS + 
two filtration step 
60 µL deuterated PBS 
containing 2 mM TSP in 
600 µL of extract 
TOCSY & HSQC Aging induces  4-
hydroxyphenylacetate, histidine, 
formate, succinate and  α-
ketoisocaproate,  α-
ketoisovalerate, 
 -hydroxybutyrate, bile salts, 
isoleucine, methionine 
Calvani et al., 
2014 
 Colorectal cancer 
human 
1:3 (wN/Av) feces 
in deuterated PBS + 
vortexing and 
centrifugation 
50 µL TSP (4 mM) in D2O 
added in 500 µL 
supernatant 
N/A N/A Bezabeh et al. 
2009 
NMR 500 MHz Experimental 
optimisation, mice 
1:10 mg.µL−1 
feces-to-buffer 
ratio, tissuelyser 
N/A COSY, TOCSY, HSQC, 
HMBC 
Identification of 40 metabolites Wu el al., 
2010 
NMR 600 MHz Ulcetative colitis 
activity, humans 
1:2 (WN/Av) feces 
to PBS, vortexing, 
cenrifugation and 
filtration 
4 µL of D2ON/A500 µM 
TSP with 40 µL of fecal 
extract 
CPMG Active UC induces  BCAAs, 
lysine, alanine, taurine 
Bjerrum et al. 
2014 
 Antiobiotic 
treatment 
(gentamicine, 
ceftriaxone), mice 
1:10 feces to PBS, 
freeze–thaw 
treatment, 
tissuelysr, 
centrifugation 
30% D2O, 0.002% TSP, 
0.03% 
of Na3N (wN/Av) 
COSY, TOCSY, JRES, 
HSQC, HMBC 
Antibiotic induces  
oligosacharides. phenolic acids 
and  SCFAs, uracil, 
hypoxanthine 
Zhao et al., 
2013 
 Age, rat 1:10 feces to PBS, 
vortexing, freeze–
thaw, tissuelyser, 
centrifugation 
0.1 M 
K2HPO4N/ANaH2PO4, pH 
= 7.4, containing 10% 
D2O, 0.58 mM TSP 
COSY, TOCSY, HSQC, 
HMBC, DOSY 
Aging induces  arabinose, 
xylose, galactose, arabinoxylan, 
propionate and inosine and  
taurine, xylose, arabinose, 
galactose, 
arabinoxylans 
Tian et al., 
2012 
 Infection 
Schistosoma 
2 fecal pellets 
homogenized in 
PBS containing 0.01% TSP CPMG, COSY, TOCSY Infection induces  5-
Aminovalerate, SCFAs 
Li et al., 2011 
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mansoni, mice 700 µL PBS, 
sonication, 
centrifugation 
(propionate) 
 IBS and UC, 
human 
1:50 (wN/Av) feces 
to PBS, 
centrifugation, 
filtration 
deuterated PBS 
containing 1 mM TSP 
COSY, HSQC, HMBC UC induces  taurine and 
cadaverine, IBS induces  bile 
acids and  BCFAs 
Le Gall et al., 
2011 
 ProN/Aprebiotics, 
mice 
1:12 (wN/Av) 
mashed feces to 
PBS, centrifugation 
60 µL DSS (5 mM) in D2O 
added in 600 µL 
supernatant 
TOCSY,HMBC,HSQC Prebiotic induces  threonine, 
alanine, glutamate, glutamine, 
aspartate, lysine, lycine, 
butyrate, uracil, hypoxanthine 
and  monosaccharides, 
glucose, trimethylamine. Pre and 
probiotic  trimethylamine and 
 acetate, butyrate, glutamine 
Hong et al., 
2010 
 Colorectal cancer, 
human 
1:2 feces to 
distilled water, 
homogenization, 
freezing, thawing, 
centrifugation 
100 µL D2O to 500 µL 
fecal water 
TOCSY Cancer induces  acetate, 
butyrate 
Monleon et 
al., 2009 
 Grape juce and 
wine extract 
consumption, 
human 
1:20 (wN/Av) feces 
to cold D2O or 
CD3OD, vortexing, 
centrifugation 
D2O or CD3OD containing 
1 mM TSP 
CPMG Grape juce consumption + wine 
induces  isobutyrate 
Jacobs et al., 
2008 
 Effect of Species, 
storage, 
lyophilization, 
sonication, 
filatrtiona nd 
homognisation  
N/A N/A COSY, TOCSY, HSQC, 
HMBC 
Storage:  alanine, glutamate, 
threonine, aspartic acid, BCAAs, 
glucose. Lyophilization:  BCAAs 
and  succinate, SCFAs. 
Sonication:  uracil, glucose and 
 SCFAs 
Saric et al., 
2008 
 UC, human 1:2 (wN/Av) feces 
to PBS, vortexing, 
filtration, 
centrifugation 
200 µL buffer (10% D2O 
& 0.01% TSP) in 400 µL 
fecal water 
COSY, TOCSY UC induces  acetate, butyrate, 
methylamine, TMA and  
isoleucine, leucine, lusine 
Marchesi et 
al., 2007 
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NMR 700 MHz Lactobacillus 1:2 (wN/Av) feces 
to detarated PBS, 
tissue lyser, 
centrifugation  
Fecal water extracted in 
9:1 D2ON/AH2O and 0.05 
% TSP 
Noesy L. helveticus induces  butyrate, 
lactate and incresed Lactobacillus 
level induces  phenylalanine, 
tyrosine, lysine, lactate, 
propionate, valine, leucine, 
isoleucine, butyrate, acetate.  
Le Roy et al., 
2015 
NMR 850 MHz Baytrill treatment, 
mice 
1:2 (wN/Av) feces 
to PBS, vortexing, 
centrifugation 
200 µL buffer 10% D2O 
and 0.01% TSP in 400 µL 
fecal water 
CPMG Treament induces  alanine, 
butyrate, isoleucine, leucine, 
propionate, threonine, valine and 
 urea 
Romick-
Rosendale et 
al., 2009 
GC-MS Colorectal cancer 
human 
oximation and 
silylation  
lyophilized human feces N/A Cancer patients butyrate, poly 
and monounsaturated fatty 
acids, ursodeoxycholic acid and 
 acetate, amino acids 
Weir et al., 
2013 
 VOCs irritable 
bowel syndrome, 
active Crohn’s 
disease, ulcerative 
colitis 
SPME human feces N/A 240 metabolites; esters of short 
chain fatty acids, 
cyclohexanecarboxylic 
acid associated with irritable 
bowel syndrome 
Ahmed, 
Greenwood, 
de Lacy 
Costello, 
Ratcliffe, & 
Probert, 2013 
 technical paper trimethylsilylation  human fecal water N/A 133 compounds structurally 
confirmed; 33 quantified 
Gao, Pujos-
Guillot, & 
Sébédio, 2010 
 technical paper ethyl 
chloroformate 
derivatization  
human fecal water N/A 73 compounds identified; 34 
validated by reference standards 
Gao et al., 
2009 
GC-TOF-MS  technical paper oximation and 
silylation  
lyophilized human feces N/A 107 metabolites matched with 
mass spectra libraries, influence 
of blood on fecal metabolome 
Phua, Koh, 
Cheah, Ho, & 
Chan, 2013 
 Colorectal cancer 
human 
oximation and 
silylation  
lyophilized human feces N/A fecal metabolomic profiles of 
patients clearly differ from 
healthy subjects 
Phua et al., 
2014 
GC-MS, GC-FID VOCs, technical 
paper 
SPME human feces N/A evaluation of eight different 
commercially available SPME 
Dixon et al., 
2011 
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UPLC-
MSN/ATOF-MS  
liver cirrhosis, 
hepatocellular 
carcinoma  
homogenization, 
centrifugation, 
filtration 
human feces N/A Cancer patients  
chenodeoxycholic acid, 7-
ketolithocholic acid, 
urobilinogen, urobilin and  
lysophosphatidylcholine (LPC) 
16:0 and 18:0  
Cao et al., 
2011 
UHPLC-TOF-MS Effect of 
consumption of 
red wine  
mixing with saline 
solution, 
centrifugation, 
filtration  
human feces N/A 37 metabolites related to wine 
intake 
Jiménez-Girón 
et al., 2015 
UPLC-Q-TOF-MS chronic renal 
failure 
homogenization, 
extraction with 
acetonitrile 
rat feces N/A renal failure  
chenodeoxychrolic acid, palmitic 
acid, adenine, phytosphingosine, 
monoglycerol 24:1, 12-hydroxy-
3-oxochola- 
dienic acid, 
lysophosphatidylethanolamine 
18:2 and 16:0 and  7-
ketolithocholic acid 
Zhao, Cheng, 
Wei, Bai, & 
Lin, 2012 
LC-MS, LC-UV technical paper Dried fecal samples 
extraction with 
water and 
acetonitrile, 
derivatization with 
dansyl chloride 
human feces N/A 67 metabolites (mainly amino 
acids) identified  
Su et al., 2015 
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